ANI Pharmaceuticals (ANIP) to Post Quarterly Earnings on Friday

ANI Pharmaceuticals (NASDAQ:ANIP) is expected to be announcing its Q2 2026 results before the market opens on Friday, August 7th. Analysts expect ANI Pharmaceuticals to post earnings of $2.04 per share and revenue of $260.1290 million for the quarter. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Individuals can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 7, 2026 at 8:00 AM ET.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, beating the consensus estimate of $1.28 by $0.77. The business had revenue of $237.46 million for the quarter, compared to the consensus estimate of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company’s revenue was up 20.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.70 earnings per share. On average, analysts expect ANI Pharmaceuticals to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $79.88 on Thursday. The firm has a market capitalization of $1.82 billion, a PE ratio of 20.22 and a beta of 0.44. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. The company has a 50-day moving average price of $80.99 and a two-hundred day moving average price of $79.39. ANI Pharmaceuticals has a twelve month low of $64.99 and a twelve month high of $99.50.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ANIP. Canaccord Genuity Group started coverage on shares of ANI Pharmaceuticals in a research note on Thursday, July 16th. They set a “hold” rating and a $91.00 price target on the stock. Guggenheim reiterated a “buy” rating and issued a $124.00 price objective on shares of ANI Pharmaceuticals in a research note on Friday, July 10th. Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Finally, Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Six research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $105.00.

Insider Activity at ANI Pharmaceuticals

In related news, CFO Stephen P. Carey sold 3,313 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $86.00, for a total transaction of $284,918.00. Following the sale, the chief financial officer owned 177,543 shares of the company’s stock, valued at approximately $15,268,698. This represents a 1.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 2,772 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $79.50, for a total transaction of $220,374.00. Following the completion of the sale, the senior vice president owned 78,696 shares in the company, valued at $6,256,332. This represents a 3.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 88,029 shares of company stock valued at $6,954,472 in the last quarter. 8.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Maryland State Retirement & Pension System grew its position in ANI Pharmaceuticals by 5.4% during the fourth quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock valued at $206,000 after acquiring an additional 134 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in shares of ANI Pharmaceuticals by 1.0% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock worth $1,267,000 after acquiring an additional 198 shares during the last quarter. Federation des caisses Desjardins du Quebec lifted its holdings in shares of ANI Pharmaceuticals by 0.6% in the 4th quarter. Federation des caisses Desjardins du Quebec now owns 39,391 shares of the specialty pharmaceutical company’s stock worth $3,110,000 after acquiring an additional 221 shares during the last quarter. Amundi grew its holdings in shares of ANI Pharmaceuticals by 1.2% during the 3rd quarter. Amundi now owns 23,918 shares of the specialty pharmaceutical company’s stock valued at $2,202,000 after purchasing an additional 285 shares during the last quarter. Finally, Alliancebernstein L.P. grew its holdings in shares of ANI Pharmaceuticals by 1.5% during the 3rd quarter. Alliancebernstein L.P. now owns 20,310 shares of the specialty pharmaceutical company’s stock valued at $1,860,000 after purchasing an additional 300 shares during the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.